Side Effects: Increased ROI

$2.8 billion pharmaceutical ad dollars are wasted annually, with most ads reaching a large group of people who are irrelevant for the product. As a pharmaceutical brand, how can you better measure and grow real world purchases of medication against the intended target audience, increasing ROI?

This discussion will delve into the pivotal roles of big data, robust identity solutions and cross-platform measurement in helping pharmaceutical advertisers navigate an increasingly fragmented ecosystem. Amidst the backdrop of evolving privacy regulations and the phasing out of traditional digital identifiers, we’ll explore the essential strategies pharmaceutical advertisers must adopt to navigate these industry challenges and accurately assess the real-world outcomes they are achieving from their advertising.

(Right to Left)

Moderator: Joe Kotz (SVP, Product Sales, VA, Moderator)

Panelists: 

Jose Ferreira (EVP, Product Strategy and Transformation, CMI Media Group)

Ted Sweetser (VP of Advertising, Purple Lab)

Scott Ronay (Head of Ecosystem Partnerships, Datavant)